Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of Larazotide Acetate to Treat Celiac Disease.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject must have been diagnosed with celiac disease by biopsy for ≥ 6 months (attending physician confirmation will be accepted in lieu of a biopsy report).~* Subject must be on a gluten-free diet for at least the past 6 months.~Exclusion Criteria:~* Subject has Anti-Tissue Transglutaminase (tTG) \> 10 EU as measured by serology~* Subject intermittently consumes clinically significant quantities of non-steroidal anti-inflammatory agents (NSAIDs) and proton-pump inhibitors, within the last 3 days prior to the treatment visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 59 Years
- Healthy Volunteers: f

Study Arms:
- Larazotide acetate (Type: EXPERIMENTAL): Larazotide acetate capsules: 12 mg QD x 3 days
- Placebo (Type: PLACEBO_COMPARATOR): Placebo capsules: QD x 3 days

Based on this trial design, predict the completion outcome and termination type (if applicable).